New findings published in Nature Chemical Biology show promise for finding new solutions to treat lung cancer and other deadly diseases. Kentucky continues to lead the nation in incidence and death rates from lung cancer, and the University of Kentucky is committed to reducing these numbers.
According to the National Cancer Institute, cancer is among the leading causes of death worldwide. And of those diagnosed in the United States, lung cancer accounts for 25 percent of cancer deaths. The numbers are sobering: one out of every two patients diagnosed with lung cancer won’t survive past 12 months.
In an effort to combat this problem, a collaboration between scientists from University of Kentucky College of Pharmacy, Memorial Sloan Kettering Cancer Center, and St. Jude Children’s Research Hospital brings researchers one step closer to a solution.
A compound developed by Dean Kip Guy’s lab of UK College of Pharmacy, with research that began at St. Jude Children’s Research Hospital, now provides us with a way to block cancer-causing proteins on a cellular level.
The groundwork began more than 10 years ago when Dr. Bhuvanesh Singh, a physician-scientist at Memorial Sloan Kettering Cancer Center, identified that an increase of a protein called DCN1 led to more malignant lung cancers and shorter life spans for his patients. Of the patients he studied, those with high levels of DCN1 succumbed to the disease more quickly than those with normal levels.
Frustrated by their findings, Singh’s team set out to study the specifics of DCN1. While DCN1 is a normally occurring protein, his team found that too much of it leads directly to cancer formation. Simply put, a malignant tumor was formed when the amount of DCN1 in a cell was increased. Thus, patients with more DCN1 got sick more quickly and died faster than their counterparts.
Efforts in Brenda Schulman’s lab at St. Jude, led by biochemist Daniel Scott, established how DCN1 interacts with other proteins and controls cellular processes. Their key discovery used X-ray crystallography to show that a small modification of the partner protein to DCN1, known as UBE2M was required for DCN1 to work. This modification, N-terminal acetylation (while common) had not previously been shown to be critical to controlling activity of this specific protein. Recognizing the potential for targeting this modification, Schulman reached out to form a collaboration between the three laboratories.
Their goal: to develop a way to stop DCN1 from killing patients.
Understanding the behavior and function of DCN1 was far more ambitious than running simple tests. It was a significant step forward in understanding how proteins within a cell work.
Building upon the science from Schulman’s team, Jared Hammill from Guy’s lab and Danny Scott from Schulman’s lab worked to stop the interactions of DCN1 all together. If DCN1’s activity depended on this interaction, then it stood to reason they could create a compound to intervene and stop the interaction from happening.
Guy describes the interaction as a “lock and key model.” Scientists have a blank key—which is UBE2M—and a lock, which is DCN1. The key wants to fit into the lock so it’s modified until it fits. This modification process is N-terminal acetylation.
“What’s the significance?” Guy said. “Well, we’re the first people to show that protein interaction controlled by N-terminal acetylation can be blocked. We’re essentially jamming the lock with a compound so the key won’t fit.”
The items jamming that lock are a series of small molecules created in the lab. When the molecules were tested directly in cancer cells, they worked. They effectively blocked DCN1 from binding to UB2EM. After decades of collaborative research, there was finally a barrier between lock and key.
The impact of these findings for healthcare and lung cancer patients specifically could be profound.
“We are excited about the implications of this research, which offer us a meaningful solution for addressing diseases like cancer, neurodegenerative disorders, and infection,” Schulman said. “It’s exciting to collaborate with so many complementary groups of expertise and to watch how Dr. Scott and Dr. Hammill led the team. This research opens many new doors for us.”
The collaboration between these three labs could mean relief to many of those suffering from a variety of diseases.
“To have spent decades on this research and have such promising results is truly exhilarating,” Singh said. “At the end of the day, what matters most is improving health outcomes for our patients. This work represents a very important step towards developing a new approach to treat the most difficult of cancers and hopefully increase cure rates.”
The Latest on: Block cancer
- With community in his corner, Union County coach Brian Thompson battles canceron October 14, 2019 at 4:55 am
Tell me who to block. I don’t need to know what’s behind me ... We had a great day. It was special to me. Cancer has touched my family, too, and it was something I was glad to be able to do.” Thompson ...
- Ghana: Don't Allow Men to Stand in Your Way to Get Breast Cancer Treatment - Women Advisedon October 14, 2019 at 3:38 am
Women diagnosed with breast cancer should not allow men to stand in their way of treatment ... "As much as possible get your husband to agree with you but if he does not, do not allow him to be a ...
- Breast cancer knows no age limitson October 14, 2019 at 2:38 am
Breast cancer doesn’t adhere to any rules — or age restrictions ... Lee started chemo six weeks after her surgery and finished a couple of months ago. She is also taking medications to block hormones.
- A touch of blue for breast cancer awareness: Men with breast cancer speak out about the need for screeningson October 13, 2019 at 11:38 am
The results, however, were questionable. He then had a biopsy, which came back with a positive diagnosis of cancer. Heller continues to take tamoxifen to block estrogen and reduce the risk of ...
- Sibley Memorial Hospital Turns to Nerve Blocks Instead of Opioidson October 11, 2019 at 9:07 pm
A nerve block is a type of regional anesthesia that uses pain medication to numb the nerves ... People who need opioids as part of their cancer treatment or have become dependent on opioids for their ...
- Vaccine against gastrin may slow spread of pancreatic canceron October 10, 2019 at 2:22 pm
New research suggests a vaccine that blocks a digestive hormone may slow the spread of pancreatic cancer, potentially increasing survival rates. The study, published ahead of print in the American ...
- Sisters share cancer battle story to raise awarenesson October 10, 2019 at 6:25 am
A woman whose sister survived breast cancer thanks to early detection has shared her gratitude during Breast Cancer ... “Chemotherapy made me really poorly sometimes but I was determined to go for a ...
- Gene-based therapy helps fight advanced prostate canceron October 10, 2019 at 6:00 am
Studies reported at meetings are generally considered preliminary until they are published in a peer-reviewed journal. Lynparza is one of a newer class of drugs called PARP inhibitors, which block a ...
- Big Pharma Bets on Body’s Garbage-Disposal System to Beat Canceron October 10, 2019 at 3:00 am
or kidney cancer. Drugs that block the proteasomes behind the recycling, including Takeda Pharmaceutical Co.’s Velcade, are already available to treat multiple myeloma, whose fast-growing cells turn ...
- Experts question how stress might affect breast canceron October 9, 2019 at 10:45 am
"The cancer cells may have some receptors, protein that communicate with stress hormones and if you can block this relationship between the hormones and the cancer cells perhaps over time, the cancer ...
via Google News and Bing News